solid enough pay
report anoth quarter gener solid oper result
segment out-performance pharma sizabl ep guidanc
increas quarter realli ton hole poke everyth
bit better oper non-oper basi flow
better outlook vs expect manag provid
color becom focu go forward although seem impli
confid current state busi higher estim increas
price object ep roll forward multipl
aid group multipl expans still premium target
two drug distributor dont think deserv level premium
especi normal opioid litig cost ad back add
abc price-to-earnings therefor reiter under-perform rate
ep higher opex lower non-oper item
increas ep ep
increas base flow-through quarter well better
oper leverag sg lower non-oper expens revenu estim
chang quit minim model also assum pharmedium remain
uncertainti busi model given consent decre memphi facil
pace remedi effort
upcom event catalyst
rest distributor import near-term data point
brand price increas brand manufactur commentari remaind
first quarter well gener price also peer report earn
on-going broad opioid litig remain question entir channel
manufactur includ variou case make way judici
system final follow manag commentari strateg evalu
pharmedium progress would like serv posit catalyst given
net dbt
outlook focu rel premium
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug distributor us
sizabl global gener sourc joint ventur
partnership
anim health unit oper
companion product anim distribut
transport logist technolog
compani base chesterbrook pa
under-perform rate driven uncertainti
on-going pharmedium closur creat
addit margin drag see concern
profit squeez across pharma suppli chain
subsector would expect distributor like
whose pharmaci struggl
reimburs pressur feel
squeez addit expect
continu premium cah/mck see
spread close
fulli recogn put two quarter oper out-performance
similar one bigger question howev rel
multipl differenti given number macro issu face
sector drug price opioid litig exposur impact compani
rel specialti exposur faster growth higher total ebit growth warrant
premium view current premium wide
exhibit abc multipl re-widen vs closest peer
exhibit rel still lowest rel valuat spread
adjust ep y/i primarili due higher oper incom lower
share count lower net interest expens
oper margin compani lap headwind pharmedium
notabl success increas penetr within exist health system custom
total revenu primarili due growth mwi consult
mwi report first revenu quarter due strong growth
oper incom y/i lap challeng quarter
see growth multipl busi
provid financi guidanc end fiscal year
strong margin segment quarter detail
feel good quarter margin perform
strong valu proposit fairli compens
increas margin due strong margin specialti specialti
physician servic wrap-around servic benefit margin
havent seen inflect store prescript growth good
perform come sustain
saw solid growth us busi leverag us
prescript drug one best manufactur industri
us
broad portfolio client drove beat specialti physician practic
health system outperform
one-tim benefit quarter
intern health benefit expens better anticip due
lower claim experienc chang benefit design
begin year contribut coupl penni
audit process complet pharmedium
audit two open facil progress progress
compani continu oper two facil continu
comprehens strateg financi review pharmedium
earli specul futur decis
pharmedium headwind slight tailwind
smaller oper loss dont expect headwind
expect process complet month
first time gener launch calendar strong amount
exclus launch track versu expect
price object base ep roll forward
multipl five-year averag five-year high
although would argu artifici high due period gener inflat
also repres bigger discount vs last five year think
discount warrant given incorpor modest growth slowdown seen
rest suppli chain well encompass competit risk
upsid risk po potenti volum pickup increas buyside/sellsid
spread opportun cost save deepen relationship
walgreen largest custom downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market lack avail
attract capit deploy opportun uncertainti across market
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
